01The therapeutic device paradox
Therapeutic devices establish that specified electromagnetic protocols can modify biological function: examples include stimulation, phototherapy and TTFields. Keep regulatory authorization, experimental demonstration and patent claims separate. Kim 2026i reports an engineered gene-switch system using 60 Hz burst repetition with a 4 kHz intraburst structure. Genome-wide CRISPR results identify CYB5B as a required component and candidate sensor; direct sensing must be separated from mediation through additional proximal-response and rescue tests. This experiment is not evidence for the same effect under an ambient 60 Hz sinusoid.
The constructive comparison is protocol-specific: local field → receiving machinery → proximal signal → clinical or cellular function. Medical efficacy anchors the possibility of a controlled physical intervention. Environmental relevance then requires the corresponding local waveform, dose, tissue transfer and functional endpoint; it is not obtained by equating frequency bands or regulatory purposes.
Compare cortical DC stimulation and ambient RF only after their frequency-dependent tissue transfer and receptor coupling are specified. Equal V/m numbers do not identify the same intracellular driver. The TTFields patenti names gonadal tissues as a design concern; a patent does not measure reproductive harm from LED drivers. These examples motivate controlled translation experiments.
| Citation | Year | Note |
|---|---|---|
| EBI Bone Healing System (FDA PMA)i | 1979 | PEMF non-thermal bone healing, 1–100 Hz |
| NeuroStar rTMS (FDA 510(k))i | 2008 | Neuroplastic changes from pulsed magnetic fields |
| Optune TTFields (FDA PMA, EF-14 phase III)i | 2015 | 100–300 kHz disrupts cell division (non-thermal) |
| Flow Neuroscience tDCS (FDA PMA)i | 2025 | 0.3–1.0 V/m DC changes brain function |
| GammaCore VNS (FDA 510(k))i | 2017 | Vagus nerve stimulation, systemic anti-inflammatory |
| Novocure patent US 7,016,725i | 2006 | Identifies ovaries/testicles as sensitive to IF fields |
| Kim et al. (Cell)i | 2026 | Engineered CYB5B-dependent gene response; 60 Hz bursts with 4 kHz intraburst structure; sensing versus mediation remains to be separated |
| US Patent 4,850,959i | 1989 | Resonance-frequency EMF controls insulin release via Ca²⁺ channels in pancreatic beta cells |
The Spectrum of Proof
Non-thermal biological effects are regulatory-approved across the entire EM spectrum — except at telecom RF frequencies
- Cellular700 MHz–3.5 GHz
- Wi-Fi2.4–6 GHz
The only frequency range where non-thermal bioactivity is 'not recognized' is the range used by the telecommunications industry
| Frequency | Device | FDA status | Mechanism | BERM pathway |
|---|---|---|---|---|
| DC | Bone growth stimulator | PMA 1986 | DC current directs osteoblast migration via bioelectric code | T_BE |
| DC | tDCS (Flow Neuroscience) | PMA 2025 | 0.3–1.0 V/m modulates cortical excitability | D |
| DC | Wound healing electrotherapy | 510(k) | Microcurrent accelerates epithelial cell migration | T_BE |
| DC | Iontophoresis | 510(k) | DC field drives charged drug molecules through tissue | T_BE |
| Frequency | Device | FDA status | Mechanism | BERM pathway |
|---|---|---|---|---|
| 2–150 Hz | TENS | 510(k) ×12,000+ | Pulsed current activates gate control and endorphin release | D |
| 1–100 Hz | PEMF bone healing | PMA 1979 | Activates adenosine A2A/A3 receptors (GPCR pathway) | GPCR |
| 1–50 Hz | rTMS (NeuroStar) | 510(k) 2008 | Pulsed magnetic field induces lasting neuroplastic changes | D |
| 130–185 Hz | DBS (deep brain stimulation) | PMA 1997 | Electrical pulses modulate basal ganglia circuits | D |
| 1–30 Hz | VNS (GammaCore) | 510(k) 2017 | Vagus nerve stimulation → systemic anti-inflammatory cascade | E |
| 2–1200 Hz | SCS (spinal cord stimulation) | PMA | Dorsal column stimulation modulates pain signaling | D |
| 0.5 Hz | CES (Alpha-Stim) | 510(k) | Microcurrent pulses modulate brainstem neurotransmitters | D |
| 20–50 Hz | FES (functional electrical stim) | 510(k) | Patterned stimulation restores motor neuron activation | D |
| 10–20 Hz | Sacral neuromodulation (InterStim) | PMA 1997 | Sacral nerve modulation restores bladder/bowel control | E |
| 100–8000 Hz | Cochlear implant | PMA 1984 | Pulsed current directly stimulates auditory nerve fibers | D |
| 20–120 Hz | EMS (muscle stimulation) | 510(k) | Electrical pulses contract skeletal muscle non-thermally | D |
| 70–140 Hz | ECT (electroconvulsive therapy) | Class III | Brief pulse current induces controlled seizure for depression | D |
| Frequency | Device | FDA status | Mechanism | BERM pathway |
|---|---|---|---|---|
| 100–500 kHz | TTFields (Optune) | PMA 2011/2015/2026 | Disrupts mitotic spindle formation (non-thermal) | A_mitotic |
| 1–4 kHz | Interferential current therapy | 510(k) | Two crossed AC currents produce deep-tissue stimulation | D |
| 300 kHz–5 MHz | RF ablation (AM-modulated) | Approved | Amplitude-modulated RF: non-thermal anticancer effect | A |
| Frequency | Device | FDA status | Mechanism | BERM pathway |
|---|---|---|---|---|
| 27.12 MHz | PRF anti-inflammatory | 510(k) | Pulsed RF produces non-thermal anti-inflammatory tissue response | A |
| Frequency | Device | FDA status | Mechanism | BERM pathway |
|---|---|---|---|---|
| 620–1100 nm | LLLT / Photobiomodulation | 510(k) 2007 | Photon absorption by mitochondrial cytochrome c oxidase → ATP/ROS | CCO |
| 420–490 nm | Blue light therapy (jaundice) | 510(k) | Photoisomerization of bilirubin — no thermal component | photochem |
| 290–320 nm | UV phototherapy (psoriasis) | 510(k) | UV-B immunomodulation via T-cell apoptosis and cytokine shift | photochem |
| 630–690 nm | Photodynamic therapy (PDT) | PMA | Light activates photosensitizer → singlet oxygen → tumor cell death | photochem |
tDCS ≈ urban ambient
The therapeutic field strength in FDA-approved tDCS (0.3–1.0 V/m) is the same order of magnitude as measured urban ambient RF (0.67–1.51 V/m). If 0.3 V/m is biologically active enough for FDA approval, urban ambient cannot be assumed inert.
TTFields patent risk
Novocure’s TTFields patent (US 7,016,725i) explicitly states that ‘ovarian or testicular cells may be sensitive to electric fields’ at 100–300 kHz — the same frequency range as LED switched-mode power supplies found in every modern building.
Chromophore generalization
LLLT works because visible light photons are absorbed by cytochrome c oxidase (CCO) in mitochondria. RF fields affect biology through cryptochrome radical pairs (CRY). Both are chromophores — molecules whose conformation changes when they absorb specific EM frequencies. Different chromophore, same principle, same non-thermal mechanism class.
Why biological sensitivity is expected, not surprising
The human eye can detect a single photon — one quantum of electromagnetic radiation carrying ~4×10⁻¹⁹ joules, one-tenth of thermal noise energy (Vaziri et al. 2016, Nature Communicationsi). Evolution optimized this electromagnetic sensor to the quantum limit because information is valuable for survival. If evolution pushed photon detection to the single-quantum boundary, why would it not have pushed electromagnetic field detection to comparable extremes?
It did. Panagopoulos et al. 2025 (Frontiers in Public Health) demonstrate that voltage-gated ion channels respond to polarized, coherent electromagnetic fields as weak as 10⁻⁵ V/m — one hundred thousandth of a volt per meter — through the Ion Forced Oscillation mechanism. Typical environmental IF-EMF from LED drivers and power electronics ranges from 0.01 to 3 V/m, exceeding this biological threshold by a factor of 1,000 to 300,000. The ‘intensity gap’ between therapeutic devices and environmental exposure does not exist at the biological level.
There is no evolved filter for IF or RF frequencies because these frequencies did not exist in the natural environment during the 3.8 billion years of biological evolution. Ion channels are ‘wideband receivers’ with no rejection of frequencies that nature never produced. Every technical signal is a potential disruption because biological sensors cannot distinguish it from a physiological signal. This is the same reason synthetic chemicals can disrupt the endocrine system — evolution did not build defenses against molecules it never encountered.
Cell Size × Frequency Vulnerability Matrix
TTFields clinical data reveals a quantitative relationship between cell size and optimal disruption frequency: larger cells respond to lower frequencies. GBM cells (20 µm) at 200 kHz, pancreatic (25 µm) at 150 kHz, breast (30 µm) at 120 kHz, melanoma (35 µm) at 100 kHz. This is the same resonance principle BERM uses for insects (Thielens 2018i: insect body size ≈ λ/2 at Wi-Fi frequencies) but at the intracellular level.
Extrapolating to BERM's target tissues: spermatogonial stem cells (~12 µm, continuously dividing) fall in the 100–200 kHz vulnerability window — precisely the frequency range of LED switch-mode power supplies (20–200 kHz). Gut epithelial cells (~10 µm, 3–5 day turnover) fall at 150–300 kHz. Oocytes (~120 µm, largest human cells) at 30–80 kHz. Each tissue has a frequency-specific vulnerability that maps to specific environmental EMF sources.
The biological mechanism at environmental IF levels is not dielectrophoresis (DEP), which requires the high intensities used in TTFields therapy (100–300 V/m). At environmental levels (0.01–3 V/m), the mechanism is Ion Forced Oscillation (IFO-VGIC): polarized IF fields force irregular gating of voltage-gated ion channels, with a demonstrated threshold of 10⁻⁵ V/m (Panagopoulos 2025i). The frequency–cell size relationship from TTFields data indicates WHICH cells are most vulnerable, while IFO provides the INTENSITY threshold at which disruption begins.
- TTFields data (confirmed)
- BERM extrapolation (predicted)
Click a point for details
Commercial Device Paradox: Flock Off / Symterra
Flock Off (now Symterra, 10,000+ installations) is a commercial product that uses 120 Hz ELF pulses to disrupt birds’ cryptochrome-based (CRY) navigation system. The product is SOLD on the premise that EMF affects biological systems non-thermally. The mechanism is the radical pair mechanism (RPM) where ELF-EMF disrupts the quantum state of CRY protein.
Paradox: 120 Hz = second harmonic of power grid (2 × 60 Hz). CRY1/CRY2 are the SAME proteins in the human circadian clock. Cry4 is bird-specific magnetoreceptor, but 120 Hz ELF ALSO affects Cry1/Cry2 which regulate mammalian circadian rhythm. ICNIRP maintains that ELF-EMF does not affect biological systems — a company commercially sells a product that works by precisely this effect.
BERM-Eco link: Flock Off directly proves that ELF-EMF disrupts CRY navigation. BERM-Eco’s bee-Varroa cascade is based on the same mechanism. Favre & Johansson 2025i (Faraday shielding → colony recovery) is the inverse phenomenon: removing EMF restores CRY function.